Peptide LibraryEcnoglutide dosage in published studies and labels
These are the doses used for Ecnoglutide in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Ecnoglutide has no FDA-approved dosage. Human dosing comes from phase 2 and phase 3 trials in China of once-weekly injections under the skin: 1.2, 1.8 or 2.4 mg for 40 weeks in adults with overweight or obesity, with mean weight changes of -9.1%, -10.9% and -13.2% against +0.1% with placebo, and 0.4–1.2 mg in adults with type 2 diabetes.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 0.4–2.4 mg once weekly in trials (1.2–2.4 mg for weight, 0.4–1.2 mg for type 2 diabetes) |
| Route | Subcutaneous |
| Frequency | Once weekly |
| Duration studied | 20–52 weeks in the published trials |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| SLIMMER — phase 3, overweight or obesity (NCT05813795)Clinical trial · Randomized, double-blind, placebo-controlled phase 3 trial | Chinese adults with overweight or obesity without diabetes (n=664) | 1.2, 1.8 or 2.4 mg | Subcutaneous | Once weekly | 40 weeks | Mean body-weight change at week 40: -9.1% (1.2 mg), -10.9% (1.8 mg), -13.2% (2.4 mg), +0.1% (placebo) | Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2025. |
| EECOH-1 — phase 3 monotherapy, type 2 diabetes (NCT05680155)Clinical trial · Randomized, double-blind, placebo-controlled phase 3 trial | Chinese adults with type 2 diabetes on diet and exercise or one oral drug (n=211) | 0.6 mg or 1.2 mg | Not stated in the indexed abstract | Once weekly | 24 weeks | HbA1c change at week 24: -1.96% (0.6 mg), -2.43% (1.2 mg), -0.87% (placebo) | Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1). Nat Commun. 2026. |
| EECOH-2 — phase 3 versus dulaglutide, type 2 diabetes on metforminClinical trial · Open-label, randomized, active-controlled phase 3 trial | Chinese adults with type 2 diabetes on metformin (621 analysed) | 0.6 mg or 1.2 mg (compared with dulaglutide 1.5 mg) | Subcutaneous | Once weekly | 52 weeks (primary endpoint at week 32) | HbA1c fell 1.91% (0.6 mg) and 1.89% (1.2 mg) against 1.65% with dulaglutide at week 32; both doses were non-inferior | Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2). Lancet Diabetes Endocrinol. 2025. |
| Phase 2, type 2 diabetes (CTR20211014)Clinical trial · Randomized, double-blind, placebo-controlled phase 2 trial | Adults with type 2 diabetes (n=145) | 0.4, 0.8 or 1.2 mg | Injection (route not further stated in the indexed abstract) | Once weekly | 20 weeks | HbA1c change: -1.81%, -1.90% and -2.39% against -0.55% with placebo | Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Commun. 2024. |
Where sources disagree
- The published phase 3 trials enrolled Chinese adults only. Ecnoglutide is not FDA-approved, and these trial doses are not an approved dosage in the United States.
- Doses for weight management (up to 2.4 mg) were higher than those tested for type 2 diabetes (up to 1.2 mg). Its milligram doses are trial arms and are not interchangeable with semaglutide or other weekly GLP-1 drugs.